Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Adaptive Biotechnologies Corp Director's Dealing 2023

Mar 9, 2023

31660_dirs_2023-03-08_6e531feb-522b-4b09-b7e2-df282e54719b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2023-03-06

Reporting Person: SOOD NITIN (Chief Commercial Officer, MRD)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-03-06 Common Stock A 132979 Acquired 247484 Direct
2023-03-06 Common Stock S 6661 $8.57 Disposed 240823 Direct
2023-03-07 Common Stock S 9813 $8.60 Disposed 231010 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-03-06 Stock Option (right to buy) $8.46 A 199549 Acquired 2033-03-06 Common Stock (199549) Direct

Footnotes

F1: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2022.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.25 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F4: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.